|
MRPL39 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.57569973630234E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.68659999802523E-08 |
| Normal-vs-Stage2 |
1.586770E-04 |
| Normal-vs-Stage3 |
1.08749997895785E-09 |
| Normal-vs-Stage4 |
8.77342642979784E-12 |
| Stage1-vs-Stage2 |
7.991400E-01 |
| Stage1-vs-Stage3 |
1.172210E-01 |
| Stage1-vs-Stage4 |
7.879200E-03 |
| Stage2-vs-Stage3 |
2.165000E-01 |
| Stage2-vs-Stage4 |
2.823500E-02 |
| Stage3-vs-Stage4 |
1.758560E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.45830047826712E-10 |
| Normal-vs-AfricanAmerican |
1.90764999999926E-05 |
| Normal-vs-Asian |
3.64020036336399E-10 |
| Caucasian-vs-AfricanAmerican |
5.702200E-01 |
| Caucasian-vs-Asian |
8.200000E-02 |
| AfricanAmerican-vs-Asian |
5.324400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.79549996671381E-09 |
| Normal-vs-Female |
9.87479986669371E-10 |
| Male-vs-Female |
7.660800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.65359999926685E-08 |
| Normal-vs-Age(41-60Yrs) |
5.82099923818191E-11 |
| Normal-vs-Age(61-80Yrs) |
2.17419999781754E-08 |
| Normal-vs-Age(81-100Yrs) |
5.543700E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.871900E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.149000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.531000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.273800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.988010E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.362000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.268600E-01 |
| Classical-VS-Follicular |
3.035200E-01 |
| Classical-VS-Other |
6.000600E-01 |
| Classical-VS-Normal |
2.27029950394808E-10 |
| Tall-VS-Follicular |
2.454600E-01 |
| Tall-VS-Other |
4.380800E-01 |
| Tall-VS-Normal |
3.26220000002042E-06 |
| Follicular-VS-Other |
9.412000E-01 |
| Follicular-VS-Normal |
5.50590000000239E-05 |
| Other-VS-Normal |
3.945800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.9975998633015E-10 |
| Normal-vs-N1 |
1.06539999045197E-10 |
| N0-vs-N1 |
9.850000E-02 |
|
|
